Jimmy Chang – Chairman & CEO, TaiMed Biologics
With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a…
Address: 18201 Von Karman Ave, Suite 470. Irvine, CA 92612
Tel: (949) 769-6543
Web: http://www.taimedbiologics.com/
TaiMed Biologics was formed on September 4, 2007 to realize the vision of creating a world-class, innovation-based biotechnology company that will satisfy the unmet medical needs of patients around the world.
The company signed an agreement with Genentech for the licensing of Ibalizumab shortly after its formation. This drug candidate, also known as TMB-355, is a proprietary humanized anti-CD4 monoclonal antibody for the treatment of HIV/AIDS. A phase-2b clinical trial is currently underway and the coma expect the trial to be completed in Q1 2011.
With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a…
Taiwan’s biotech sector is growing rapidly and increasingly embracing advanced fields such as precision medicine and AI. However, Johnsee Lee, chairman of the Taiwan Bio Industry Organization warns that the island’s…
Rita Huang, dean of the Office of Research and Development and the director of the TMU Research Center for Cell Therapy and Regeneration Medicine highlights the center’s unique capabilities and…
NYMU President Dr Steve Kuo describes the history of the university and transformative period it is currently undergoing. Dr Kuo shares the university’s key strengths and unique strategy to merge…
Dr Michael Chang, founder and chairman of OBI Pharma, shares the history of his company’s beginnings and highlights the current progress of its innovative immune-oncology pipeline. Dr Chang goes on…
Shih-Chung Chen, Minister of Health and Welfare of the Republic of China (Taiwan), gives an update on the Ministry’s current directives under the Biomedical Industry Innovation Program to bolster Taiwan’s…
Dr Hung-Kai Kevin Chen, co-founder and CEO of Elixiron Immunotherapeutics, an innovative rising biotech focused on immunotherapeutic solutions, describes the company’s unique approach to developing new treatment methods for two…
Johnsee Lee, chairman of Taiwan Bio Industry Organization, gives an update on the major developments of the country’s biotech environment over recent years, speaking about its new areas of focus,…
Professor Chi-Hung Lin of NCTU discusses the opportunities and hurdles for unveiling smart healthcare in Taiwan. He also assesses Taiwan’s position in the global race for smart healthcare, and how…
Dar-Bin Shieh, deputy minister of science and technology of the Republic of China (Taiwan), gives an overview of Biomedical Industry Innovation Program, enacted to bolster Taiwan’s biomedical and biotechnology sectors…
Taiwan boasts one of the most sophisticated and comprehensive public health systems in Asia. However, mounting costs and the pressures of a rapidly ageing population mean that the National Health…
Taiwan’s Minister of Economic Affairs, Jong-Chin Shen, outlines the initiatives implemented by the Ministry to help Taiwan’s industries reinforce their competitive advantage. Minister Shen also goes on to explain the…
Professor Ming-Shiang Wu, director of the Taiwan Clinical Trial Consortium, elaborates on the activities of the organization and its role to promote Taiwan’s clinical trial infrastructure and attract more international…
See our Cookie Privacy Policy Here
